Key result
Tolvaptan and serelaxin emerge as the most promising nondiuretic therapies for acute heart failure decongestion.
Why the study?
Diuretic resistance during acute heart failure poses a substantial challenge, and evidence is lacking on the optimal strategies to tackle this problem.
Does adjuvant nondiuretic pharmacotherapy improve decongestion and dyspnea relief compared to standard care alone in patients hospitalised with acute heart failure?
Systematic Review
Yes
Does adjuvant nondiuretic pharmacotherapy improve decongestion and dyspnea relief compared to standard care alone in patients hospitalised with acute heart failure?
This systematic review of 23 RCTs indicates that while adjuvant tolvaptan and serelaxin show promise for improving decongestion and dyspnea in acute heart failure, substantial heterogeneity in endpoint measurement and lack of standardized diuretic protocols limit definitive clinical recommendations.
Answers are grounded in this paper and cite their sources.
Tolvaptan and serelaxin merit targeted trials in acute HF; heterogeneity precludes routine clinical adoption.
Diuretic therapy is the mainstay during episodes of acute heart failure (AHF). Diuretic resistance is often encountered and poses a substantial challenge for clinicians. There is a lack of evidence on the optimal strategies to tackle this problem. This review aimed to compare the outcomes associated with congestion management based on a strategy of pharmacological nondiuretic-based regimens. The PubMed, Cochrane Library, Scopus, and ScienceDirect databases were systematically searched for all randomised controlled trials (RCTs) of adjuvant pharmacological treatments used during hospitalisation episodes of AHF patients. Congestion relief constitutes the main target in AHF; hence, only studies with efficacy indicators related to decongestion enhancement were included. The Cochrane risk-of-bias tool was used to evaluate the methodological quality of the included RCTs. Twenty-three studies were included; dyspnea relief constituted the critical efficacy endpoint in most included studies. However, substantial variations in dyspnea measurement were found. Tolvaptan and serelaxin were found to be promising options that might improve decongestion in AHF patients. However, further high-quality RCTs using a standardised approach to diuretic management, including dosing and monitoring strategies, are crucial to provide new insights and recommendations for managing heart failure in acute settings.
No takes yet. Share an insight, caveat, or question.
Emara et al. (2022) conducted a systematic review in Acute heart failure (AHF) with congestion. Adjuvant nondiuretic pharmacotherapy (including tolvaptan, serelaxin, rolofylline, nesiritide, tezosentan, levosimendan, istaroxime, cimlanod, omecamtiv mecarbil, empagliflozin) vs. Placebo or no drug added to standard care was evaluated on Decongestion efficacy indicators ( primarily dyspnea relief, evaluated in 19 of 23 studies). Adjuvant tolvaptan and serelaxin were the most promising nondiuretic therapies for improving dyspnea and decongestion in acute heart failure across 23 RCTs, with improvement seen in 10 studies.
Synapse has enriched 10 related papers. Consider them for comparative context: